PDF factsheet
      Z

glucose lowering for cardiovascular prevention in diabetes type 2 for all type of patients, clinical trials results

aleglitazar versus placebo
ALEPREVENT,
EUDRACT201200067116
aleglitazar 150 ìg
versus
placebo
patients with T2D or prediabetes with established, stable CV diseasedouble-blind
Follow-up duration: 58 days
ALECARDIO, 2014
NCT01042769
aleglitazar 150 ìg daily
versus
placebo
patients hospitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetesdouble-blind
Follow-up duration: 2 years ( median)
alogliptin versus placebo
EXAMINE, 2013
NCT00968708
alogliptin
versus
placebo
patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 daysdouble-blind
Follow-up duration: 1.5 years (median)
canagliflozin versus placebo
CANVAS, 2017
NCT01032629
canagliflozin
versus
placebo
participants with type 2 diabetes and high cardiovascular riskdouble-blind
Follow-up duration: 188.2 weeks (mean)
dapagliflozin versus placebo
DECLARE TIMI 58, 2018
NCT01730534
Dapagliflozin
versus
adults with T2D at risk of CV events, including patients with multiple CV risk factors or established CV diseasedouble-blind
Follow-up duration: approx 4 years (median)
empagliflozin versus placebo
EMPA-REG OUTCOME, 2015
NCT01131676
10 mg or 25 mg of empagliflozin once daily
versus
placebo
patients with type 2 diabetes at high cardiovascular riskdouble-blind
Follow-up duration: 3.1 years (median)
42 countries
exenatide versus placebo
EXSCEL, 2017
NCT01144338
subcutaneous injections of extended-release exenatide at a dose of 2 mg once weakly
versus
placebo
patients with type 2 diabetes, with or without previous cardiovascular diseasedouble-blind
Follow-up duration: 3.2 years median
insulin glargine versus control
ORIGINE, 2012
NCT00069784
insulin glargine (with a target fasting blood glucose level of ¡Ü95 mg per deciliter
versus
standard care
with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes
Follow-up duration: 6.2 years
linagliptin versus glimepiride
CAROLINA, 2012
NCT01243424
linagliptin
versus
glimepiride 1-4 mg QD
patients with type 2 diabetes at elevated cardiovascular risk receiving usual caredouble-blind
Follow-up duration: 2 years
USA
liraglutide versus placebo
LEADER, 2016
NCT01179048
Maximum dose of 1.8 mg liraglutide, injected subcutaneously once daily
versus
placebo
subjects with type 2 diabetesdouble-blind
Follow-up duration: 3.8 years (median)
Africa, Asia, Europe, North and South America
lixisenatide versus placebo
ELIXA,
NCT01147250
lixisenatide
versus
placebo
patients with T2DM and a recent ACS eventdouble-blind
Follow-up duration: 25 months (median)
49 countries
metformin versus placebo
HOME, 2009
NCT00375388
metformin 850 mg
versus
placebo
patients with DM2 treated with insulindouble-blind
Follow-up duration: 4.3 y
The Netherlands
pioglitazone versus placebo
PROACTIVE,
NCT00174993
oral pioglitazone titrated from 15 mg to 45 mg
versus
placebo
patients with type 2 diabetes who had evidence of macrovascular disease.
Follow-up duration: 34.5 months
IRIS, 2016
NCT00091949

versus
rosiglitazone versus metformin/sulfonylurea
RECORD, 2013
NCT00379769

versus
saxagliptin versus placebo
SAVOR TIMI, 2013
NCT01107886
saxagliptin
versus
placebo
patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular eventsdouble-blind
Follow-up duration: 2.1 years (median)
semaglutide versus placebo
SUSTAIN 6, 2016
NCT01720446
once-weekly semaglutide (0.5 mg or 1.0 mg)
versus
placebo
patients with type 2 diabetes who were on a standardcare regimendouble-blind
Follow-up duration: 2.1 y (median)
20 countries
sitagliptin versus placebo
TECOS, 2015
NCT00790205
sitagliptin phosphate, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily
versus
placebo
patients with Type 2 Diabetes Mellitus having a history of cardiovascular disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%double-blind
Follow-up duration: 3.0 years (median)
38 countries

  Options


in first

in second

  Filter